Hydrea - anticancer drug.
Hydrea is produced in the form of capsules: gelatin solid, opaque, size №0, with an inscription in black «BMS 303" housing - matte, pale pink cap - matt, green;contents of capsules - a white powder or compacted mass (100 pieces in dark glass bottles, 1 bottle in a cardboard package, 10 pieces in blister, 2 blisters in a carton box..).
The structure of the capsule 1 includes:
capsule shell composition: Titanium dioxide - 2,016 mg gelatine - 93.743 mg Iron oxide yellow dye - 0.110 mg iron oxide red dye - 0,115 mg, indigo dye FD & amp;C Blue 2 - 0,017 mg.
ink composition: iron oxide black, shellac, propylene glycol, N-butyl alcohol, isopropyl alcohol, industrial methylated spirit, purified water.
Relative (Hydrea prescribed with caution in the presence of the following diseases / conditions):
Hydrea is taken orally.When swallowing difficulties may be available to open the capsule, pour the contents into a glass of water and drink immediately.Thus some of the insoluble auxiliary components may remain on the surface of the solution.
Dosage doctor determines individually, based on technical literature data.
During therapy need to take the liquid in sufficiently large quantities.
Depending on the indication, Hydrea is usually prescribed as follows:
In patients with impaired hepatic function should be carried out careful monitoring of blood parameters.Data on the need to change the dose in this group of patients there.
the appointment of Hydrea in patients with impaired renal function should be carried out correction dose.If creatinine clearance up to 60 ml per minute to a drug usually administered in a dose of 15 mg / kg.Patients with end-stage renal failure Hydrea should be used at the same dose twice, with an interval of 7 days: the first time - at the end of the four-hour hemodialysis session, the second - before the hemodialysis session.
Older patients are encouraged to nominate a drug in doses not exceeding 60 mg / kg per day.
Cases of hepatotoxicity and pancreatitis (with possible fatal outcome), and severe peripheral neuropathy observed in patients with HIV who were taking Hydrea simultaneously with antiretroviral drugs, in particular, together with didanosine or stavudine without him.
most private violations observed in the combined use Hydrea and radiation therapy are the same as for monotherapy - suppression of bone marrow function (anemia, leukopenia) and irritation of the gastric mucosa.Additionally, hydroxycarbamide reception can lead to an enhancement of certain side effects commonly seen when radiation therapy (mucositis, stomach discomfort).
Hydrea may be used only under the supervision of a physician who has experience in anticancer therapy.
Before the start of each course and periodically during therapy need to control the function of bone marrow, liver and kidney.Determination of white blood cells, platelets and hemoglobin should be carried out at least 1 time in 7 days, throughout the period of use of Hydrea.The therapy is prescribed only in cases where the white blood cell count above 2500 / mm, and platelets - 100,000 / microliter.By reducing the level of their therapy discontinued prior to normalization.
should compensate Prior to treatment in severe anemia.
When using Hydrea may develop myelosuppression, most often - leukopenia.Anemia and thrombocytopenia develop less frequently and in very rare cases - without prior leukopenia.The most likely development of myelosuppression in patients after recent chemotherapy other medications or radiation therapy.
Following the recent time, radiation or chemotherapy Hydrea should be used with caution because of the probability of acute post-irradiation erythema and increase the severity of side effects (ulceration of the gastrointestinal tract, dyspepsia, bone marrow aplasia).With the development of severe violations of the digestive organs, such as nausea, vomiting, anorexia, treatment is usually suspended.
When the pain and discomfort with local anesthetics and analgesics for oral mucositis occurs in the field of radiation are usually prescribed.In severe cases, treatment temporarily suspended, with very severe temporarily cancel concomitant radiotherapy.
Hydrea may delay plasma iron clearance and reduce the rate of iron utilization by erythrocytes, but it does not affect the red blood cells during life.
In the early stages of application Hydrea is often observed moderate megaloblastic erythropoiesis.Morphological changes are generally resemble pernicious anemia, but they are not associated with deficiency of folic acid or vitamin B12.Due to the fact that macrocytosis may mask a lack of folic acid, it is necessary to consider its preventive appointment the patient.
Against myeloproliferative disorders during use Hydrea observed toxic dermal vasculitis, including gangrene and ulceration of the vasculitis.The most common reported toxic vasculitis in patients treated in the past or currently receiving interferon.Taking the drug with the progression of vasculitic ulcerations should be stopped.
Prolonged use of Hydrea in patients with myeloproliferative diseases, such as polycythemia vera and thrombocythemia, secondary leukemia cases were observed.The reason for the development of secondary leukemia (receiving hydroxyurea or underlying disease) is unknown.Also, prolonged therapy may lead to the development of skin cancer, so at the time of treatment is recommended to protect the skin from sunlight and systematically self-control of its condition.When planning visits to the doctor should monitor the patient's skin covers for possible malignant change.
Since Hydrea has a cytotoxic effect at the opening of the capsules need to be careful and avoid inhalation or contact with the drug powder to the mucous membranes and skin.
Hydrea can lead to dizziness and other adverse events in the nervous system that need to be considered when managing road.
With simultaneous use of Hydrea with some drugs may cause the following effects:
If, during the combined treatment occurs severe indigestion, nausea, anorexia, or vomiting, they can usually be cut short interruption receiving Hydrea.
Mucositis (discomfort and soreness of the mucous membranes at the site of exposure) can facilitate local anesthetic and analgesic drugs (oral).In severe mucositis use Hydrea is temporarily interrupted;in very severe cases - suspended radiotherapy.
drug can increase the content of uric acid in blood serum, which may require adjusting the dose of drugs that increase the excretion of uric acid.
The interaction of enzymes and hydroxycarbamide (uricase, urease, LDH) during use Hydrea sightings false positive test results were noted when determining uric acid, urea and lactic acid.
Store protected from light, out of reach of children at a temperature of 15-25 ° C.
Shelf life - 5 years.
Klimadinon - herbal drug used during menopause syndrome. release form and composition Klimadinon available in the following dosage forms: ...
Klerasil - a series of resources to care for problem skin. Description Klerasil products under the trademark «Clearasil» released three serie...
maple - glucocorticosteroid (GCS) for topical use. release form and composition Dosage Forms: Spray for inhalation dose and a solution for ...